Related Experiment Video

Updated: Jun 15, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Angiographic treatment of high-flow priapism

P Puppo, E Belgrano, F Germinale

    European Urology
    |January 1, 1985
    PubMed

    Insights

    Percutaneous transcatheter occlusion of internal pudendal arteries offers a reversible treatment for priapism. This embolization technique preserves sexual potency by allowing natural vessel recanalization.

    Area of Science:

    • Urology
    • Interventional Radiology
    • Vascular Surgery

    Background:

    • Priapism, a persistent erection, requires prompt treatment to prevent long-term complications.
    • High-flow priapism is often associated with vascular abnormalities.
    • Current treatment options for priapism may carry risks of impotence.

    Purpose of the Study:

    • To evaluate the efficacy and safety of percutaneous transcatheter occlusion of internal pudendal arteries for treating high-flow priapism.
    • To assess the reversibility of the occlusion and its impact on sexual potency.

    Main Methods:

    • Unilateral or bilateral percutaneous transcatheter embolization of the internal pudendal arteries was performed.
    • Autologous clot was used as the embolic agent to ensure reversibility.
    • Five cases of high-flow priapism were treated and followed.

    Main Results:

    • Successful occlusion of the internal pudendal arteries was achieved in all cases.
    • The embolization procedure was reversible, with vessel recanalization occurring due to clot lysis.
    • Sexual potency was preserved in all patients treated with this method.

    Conclusions:

    • Percutaneous transcatheter occlusion of internal pudendal arteries is a feasible and effective treatment for high-flow priapism.
    • The use of autologous clot ensures reversibility, mitigating the risk of impotence.
    • This minimally invasive approach offers a specific and organ-preserving therapy for priapism.

    More Related Videos

    Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound13:48

    Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

    Published on: April 21, 2023

    Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

    Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

    Published on: January 18, 2018

    Related Concept Videos

    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...